IP Library › Patent Application 16283525
Patent Application
App. No. 16/283,525

FACTOR VIII WITH EXTENDED HALF-LIFE AND REDUCED LIGAND-BINDING PROPERTIES

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
16/283,525
Abstract

The invention relates to materials and methods of conjugating a water soluble polymer to an oxidized carbohydrate moiety of a therapeutic protein comprising contacting the oxidized carbohydrate moiety with an activated water soluble polymer under conditions that allow conjugation. More specifically, the present invention relates to a modified, recombinant Factor VIII (FVIII) with extended half-life and reduced ligand-binding properties.

Claims (1)

1 . A method of treating a hemorrhagic defect in a mammal comprising the step of administering a PSA modified FVIII, to the mammal in an amount effective to reduce or eliminate one or more symptoms of said hemorrhagic defect.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 31, 2021
From: BAXALTA GMBH; BAXALTA INCORPORATED
To: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Reel/Frame 055189/0177 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 28, 2019
From: TURECEK, PETER; SCHRENK, GERALD; SIEKMANN, JUERGEN
To: BAXALTA INCORPORATED; BAXALTA GMBH
Reel/Frame 049619/0743 →